Pfizer says its vaccine is safe & effective in 5-11 year-olds: 5 things to know

Listen
Text
  • Small
  • Medium
  • Large

Pfizer on Sept. 20 released trial data showing its COVID-19 vaccine is safe and effective in children ages 5 to 11. Here are five key details:

  1. The data comes from a phase 2/3 study that included 2,268 participants ages 5-11.

  2. The trial participants received two 10-microgram doses of Pfizer's COVID-19 vaccine, administered 21 days apart. For people ages 12 and older, Pfizer uses a 30-microgram dose.

  3. Pfizer said the trial demonstrated a "favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age." The findings have not been peer reviewed or published in a scientific journal.

  4. Pfizer said it will share this data with the FDA and other regulators as soon as possible.

  5. Of the drugmakers with a COVID-19 vaccine in use in the U.S., Pfizer is the first one to produce results from a trial testing its vaccine in children ages 5 to 11.
 

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars